Biocompounding

1. Iveric plans FDA submission of data for geographic atrophy eye-drug following study success Iveric Bio announced positive phase 3 topline data from Zimura for geographical atrophy (GA). Zimura is a novel investigational complement C5 inhibitor. Overactivity of the complement system and the C5 protein are suspected to play

1. FDA clears updated COVID-19 boosters from Pfizer, Moderna A long-awaited moment! On Wednesday, FDA approved a new version of Pfizer’s vaccine for adults and children over 12 years old and Moderna’s modified shot for adults who are 18 or older. Both vaccines are bivalent, meaning

1. Kymera raises $150 million through the sale of shares to fund development of its clinical and preclinical assets Kymera which focuses on targeted protein degradation announced that it is raising $150 million to support its ongoing research and development programs and for general corporate purposes. The biotech has three

1. Merck makes big R&D investment with $3.5B Orna deal ORNA Therapeutics recently struck a deal with Merck to collaborate on the advancement of Orna’s Next Generation of RNA Technology. What does ORNA Therapeutics do? In the next revolution in RNA therapeutics, oRNA molecules are engineered

1) Pfizer's acquisition of Global Blood Therapeutics The acquisitions continue! This week Pfizer reported that it will be acquiring Global Blood Therapeutics (GBT) for $5.4B. The proposed acquisition is expected to drive growth by bringing GBT's sickle cell disease (SCD) expertise together with a robust